Genomic sieve analysis can inform SARS-CoV-2 vaccine development

SILVER SPRING, Md. – As concern has grown over COVID-19 variants and their implications for how well COVID-19 vaccines will protect against the virus, researchers have proposed a method to examine instances of SARS-COV-2 infections in people who have received a COVID-19 vaccine.

Genomic sieve analysis of these so-called “breakthrough” SARS-CoV-2 infections in COVID vaccine trials is a critical tool to identify viral mutations associated with vaccine failure and to predict how vaccination impacts the virus’ evolution.

Dr. Morgane Rolland, Chief of Viral Genetics for the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, and Dr. Peter Gilbert, biostatistician and professor at the Vaccine and Infectious Disease and Public Health Sciences Divisions at Fred Hutchinson Cancer Research Center, described the strategy in a recent publication in


PLOS Pathogens


.

“No vaccine is 100 percent effective, so even in clinical trials for the highly effective COVID vaccines being rolled out now, some of the trial volunteers who received the vaccine experienced breakthrough infections,” explained Rolland. “Sieve analysis compares those breakthrough viruses to those that infected the placebo group to help pinpoint which variants are evading the vaccine-induced immune response and inform efforts to improve COVID vaccines.”

Gilbert added, “Think of the vaccine as a sieve and different variants as pebbles poured into the sieve: the vaccine will block some variants but allow others to pass through, and sieve analysis learns which variants make it through.”

Sieve analysis allows scientists to recognize evolutionary patterns that will be key to infer how SARS-CoV-2 might adapt to widely used vaccines and predict how virus evolution could eventually impact vaccine efficacy. The paper’s authors note SARS-CoV-2 is relatively slow to mutate, meaning it’s unlikely current vaccines will be rendered obsolete soon, but increased vigilance is needed in the months until a majority of the population has been vaccinated to stem spread of concerning variants.

“The variants that emerged in the past two months highlight the need for next generation vaccines,” said Rolland. “Conducting sieve analysis of samples obtained through vaccine trials is an efficient way to determine how future vaccines should be designed.”

###

About MHRP

The U.S. Military HIV Research Program (MHRP), part of the Walter Reed Army Institute of Research, is at the forefront of the battle against HIV/AIDS to protect U.S. troops from infection and reduce the global impact of the disease. MHRP has been recognized as a leader in HIV diagnostics, epidemiology and vaccine research for over three decades and, more recently, has built an international reputation for pioneering discoveries in acute infection and remission. Its research is supported by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and the U.S. Department of Defense (DOD). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense, or HJF.